Literature DB >> 21956414

Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Joanne Ngeow1, Jessica Mester, Lisa A Rybicki, Ying Ni, Mira Milas, Charis Eng.   

Abstract

CONTEXT: Thyroid cancer is believed to be an important component of Cowden syndrome (CS). Germline PTEN and SDHx mutations and KLLN epimutation cause CS and CS-like phenotypes. Despite the established association, little is known about the incidence and clinical features of thyroid cancer found in CS/CS-like patients.
OBJECTIVE: The aim of the study was to compare incidence, clinical, and histological characteristics of epithelial thyroid cancers in CS/CS-like individuals, in the context of PTEN, SDHx, and KLLN status. DESIGN AND PARTICIPANTS: The study encompassed a 5-yr, multicenter, prospective accrual of 2723 CS and CS-like patients, all of whom had comprehensive PTEN analysis. SDHx mutation analysis occurred in those without PTEN mutations/variations and elevated manganese superoxide dismutase (MnSOD) levels. KLLN epimutation analysis was performed in the subset without any PTEN or SDHx mutation/deletion/ variant/polymorphism. MAIN OUTCOME MEASURES: Gene-specific thyroid cancer histologies, demographic and clinical information, and adjusted standardized incidence rates were studied.
RESULTS: Of 2723 CS/CS-like patients, 664 had thyroid cancer. Standardized incidence rates for thyroid cancer were 72 [95% confidence interval (CI), 51-99; P < 0.001] for pathogenic PTEN mutations, 63 (95% CI, 42-92; P < 0.001) for SDHx variants, and 45 (95% CI, 26-73; P < 0.001) for KLLN epimutations. All six (16.7%) diagnosed under age 18 yr carried pathogenic PTEN mutations. Follicular thyroid cancer was overrepresented in PTEN mutation-positive cases compared to those with SDHx and KLLN alterations. PTEN frameshift mutations were found in 31% of patients with thyroid cancer compared to 17% in those without thyroid cancer.
CONCLUSIONS: CS/CS-like patients have elevated risks of follicular thyroid cancer due to PTEN pathogenic mutations and of papillary thyroid cancer from SDHx and KLLN alterations. Children presenting with thyroid cancer should be tested for PTEN mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956414      PMCID: PMC3232626          DOI: 10.1210/jc.2011-1616

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

3.  Localization of the gene for Cowden disease to chromosome 10q22-23.

Authors:  M R Nelen; G W Padberg; E A Peeters; A Y Lin; B van den Helm; R R Frants; V Coulon; A M Goldstein; M M van Reen; D F Easton; R A Eeles; S Hodgsen; J J Mulvihill; V A Murday; M A Tucker; E C Mariman; T M Starink; B A Ponder; H H Ropers; H Kremer; M Longy; C Eng
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

6.  Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.

Authors:  Xiao-Ping Zhou; Kristin A Waite; Robert Pilarski; Heather Hampel; Magali J Fernandez; Cindy Bos; Majed Dasouki; Gerald L Feldman; Lois A Greenberg; Jennifer Ivanovich; Ellen Matloff; Annette Patterson; Mary Ella Pierpont; Donna Russo; Najah T Nassif; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

7.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Authors:  Hartmut P H Neumann; Christian Pawlu; Mariola Peczkowska; Birke Bausch; Sarah R McWhinney; Mihaela Muresan; Mary Buchta; Gerlind Franke; Joachim Klisch; Thorsten A Bley; Stefan Hoegerle; Carsten C Boedeker; Giuseppe Opocher; Jörg Schipper; Andrzej Januszewicz; Charis Eng
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

8.  Familiality of cancer in Utah.

Authors:  L A Cannon-Albright; A Thomas; D E Goldgar; K Gholami; K Rowe; M Jacobsen; W P McWhorter; M H Skolnick
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

9.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.

Authors:  D E Goldgar; D F Easton; L A Cannon-Albright; M H Skolnick
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506

10.  The Cowden syndrome: a clinical and genetic study in 21 patients.

Authors:  T M Starink; J P van der Veen; F Arwert; L P de Waal; G G de Lange; J J Gille; A W Eriksson
Journal:  Clin Genet       Date:  1986-03       Impact factor: 4.438

View more
  62 in total

1.  Germline PARP4 mutations in patients with primary thyroid and breast cancers.

Authors:  Yuji Ikeda; Kazuma Kiyotani; Poh Yin Yew; Taigo Kato; Kenji Tamura; Kai Lee Yap; Sarah M Nielsen; Jessica L Mester; Charis Eng; Yusuke Nakamura; Raymon H Grogan
Journal:  Endocr Relat Cancer       Date:  2015-12-23       Impact factor: 5.678

2.  Assessment of PTEN-associated vascular malformations in a patient with Bannayan-Riley-Ruvalcaba syndrome.

Authors:  Sandra Anusic; Robert Karl Josef Clemens; Thomas Oleg Meier; Beatrice Ruth Amann-Vesti
Journal:  BMJ Case Rep       Date:  2016-06-29

Review 3.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

4.  A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.

Authors:  Fang Feng; Lamis Yehia; Ying Ni; Yi Seok Chang; Sissy Meihua Jhiang; Charis Eng
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

Review 5.  Colorectal cancer risk in hamartomatous polyposis syndromes.

Authors:  Fábio Guilherme Campos; Marleny Novaes Figueiredo; Carlos Augusto Real Martinez
Journal:  World J Gastrointest Surg       Date:  2015-03-27

Review 6.  [Hereditary tumor syndromes in neuropathology].

Authors:  C Mawrin
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

7.  Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?

Authors:  S Adeleh Razavi; Mohammad Hossein Modarressi; Parichehr Yaghmaei; S Mohammad Tavangar; Mehdi Hedayati
Journal:  Endocrine       Date:  2017-07-28       Impact factor: 3.633

8.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16

10.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.